Related Experiment Video

Updated: Oct 9, 2025

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way

Published on: May 10, 2021

Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node

Wan-Yu Chen^1,2,3, Ku-Hao Fang⁴, Chun-Wei Wang^1,5,6

¹Division of Radiation Oncology, Department of Oncology National Taiwan University Hospital Taipei Taiwan.

Laryngoscope Investigative Otolaryngology

|December 23, 2021

Abstract

Objective:

Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1_new in this study).

Methods:

A total of 243 low/intermediate risk pN1_new patients with oral cavity cancer who received curative surgery were included. Overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were compared between patients receiving adjuvant treatment and observation alone.

Results:

For patients receiving adjuvant therapy vs observation, the differences in outcomes were not statistically significant in terms of 5-year OS, LRFS, RRFS, and DMFS. For subgroup analysis, in low/intermediate pN1_new patients with one or more minor risk factors, adjuvant therapy was not significantly associated with OS, LRFS, RRFS, or DMFS in pN1_new patients.

Conclusion:

For low/intermediate risk pN1_new patients with oral cavity cancer, adjuvant therapy might be omitted.

Level Of Evidence:

4.

Keywords:

adjuvant radiotherapy oral cancer risk factor single node surgery

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Articles linked to this work by shared authors, journal, and citation graph.

Is Curative-Intent Primary Surgery Beneficial for Geriatric Oral Cavity Squamous Cell Carcinoma Patients?

Head & neck·2026

Risk of post-radiation hypothyroidism among different head and neck cancer subsites and radiation therapy techniques.

Journal of the Formosan Medical Association = Taiwan yi zhi·2026

Diagnostic Performance of Duplex Ultrasonography in Post-Radiation Common Carotid Artery Stenosis: A Cross-Sectional Validation Study.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine·2026

Surgery alone achieves comparable survival to adjuvant therapy in T4aN0M0 gingival squamous cell carcinoma with clear surgical margins: A registry-based propensity-matched analysis.

Oral oncology·2026

Dose comparison of proton beam therapy with and without a multileaf collimator in the treatment of multiple hepatocellular carcinoma.

Physics and imaging in radiation oncology·2026

Intensity-modulated proton therapy for patients with unresectable giant (≥ 10 cm) hepatocellular carcinoma: a retrospective analysis from two high-volume centers.

Japanese journal of radiology·2026

See all related articles